ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
-1.02%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$238M
AUM Growth
+$238M
(-15%)
Cap. Flow
-$23.3M
Cap. Flow
% of AUM
-9.8%
Top 10 Holdings %
Top 10 Hldgs %
62.29%
Holding
58
New
11
Increased
7
Reduced
11
Closed
21
Top Buys
| 1 |
Apellis Pharmaceuticals
APLS
|
$21.7M |
| 2 |
Relmada Therapeutics
RLMD
|
$9.1M |
| 3 |
Pyxis Oncology
PYXS
|
$7.44M |
| 4 |
Merus
MRUS
|
$3.61M |
| 5 |
Viridian Therapeutics
VRDN
|
$3.6M |
Top Sells
| 1 |
BLU
BELLUS Health Inc.
BLU
|
$11.9M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$11.1M |
| 3 |
Clearside Biomedical
CLSD
|
$7.9M |
| 4 |
Xenon Pharmaceuticals
XENE
|
$6.01M |
| 5 |
Cartesian Therapeutics
RNAC
|
$4.26M |
Sector Composition
| 1 | Healthcare | 92.25% |
| 2 | Financials | 5.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
WHWK
1
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $36.9M | 15.53% | 1,529,402 | – | – |
|
|
2
Apellis Pharmaceuticals
APLS
$3.48B
| $25.3M | 10.63% | 535,000 +459,500 | +609% | +$21.7M |
|
3
VistaGen Therapeutics
VTGN
$102M
| $22.9M | 9.62% | 11,736,283 +8,250 | +0.1% | +$16.1K |
|
4
Celldex Therapeutics
CLDX
$1.47B
| $13.1M | 5.52% | 340,098 +2,598 | +0.8% | +$100K |
|
5
GH Research
GHRS
$837M
| $9.79M | 4.12% | 419,632 +26,382 | +7% | +$615K |
|
|
6
Relmada Therapeutics
RLMD
$37.2M
| $9.1M | 3.83% | +404,000 | New | +$9.1M |
|
|
BLSA
7
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $8.26M | 3.47% | 843,122 | – | – |
|
|
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $7.86M | 3.3% | 470,000 -665,000 | -59% | -$11.1M |
|
|
9
Merus
MRUS
$4.98B
| $7.49M | 3.15% | 235,500 +113,500 | +93% | +$3.61M |
|
|
10
Pyxis Oncology
PYXS
$79.4M
| $7.44M | 3.13% | +677,753 | New | +$7.44M |
|
|
11
Xenon Pharmaceuticals
XENE
$2.98B
| $7.03M | 2.95% | 225,000 -192,409 | -46% | -$6.01M |
|
12
Arrowhead Research
ARWR
$3.05B
| $7M | 2.94% | 105,500 -16,000 | -13% | -$1.06M |
|
|
13
Viridian Therapeutics
VRDN
$1.5B
| $6.29M | 2.64% | 318,000 +182,193 | +134% | +$3.6M |
|
|
JYAC
14
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
| $5.5M | 2.31% | 562,500 | – | – |
|
15
Syndax Pharmaceuticals
SNDX
$1.41B
| $4.51M | 1.9% | 206,126 | – | – |
|
|
CYT
16
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $4.46M | 1.87% | 391,974 | – | – |
|
|
BLU
17
DELISTED
BELLUS Health Inc.
BLU
| $4.23M | 1.78% | 525,000 -1,482,500 | -74% | -$11.9M |
|
18
Kura Oncology
KURA
$686M
| $4.09M | 1.72% | 291,884 | – | – |
|
|
SEEL
19
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $4.08M | 1.71% | 2,500,000 -360,000 | -13% | -$587K |
|
20
Athira Pharma
ATHA
$15.3M
| $4.04M | 1.7% | 310,030 +12,668 | +4% | +$165K |
|
21
Orchestra BioMed
OBIO
$147M
| $3.96M | 1.66% | 392,500 | – | – |
|
22
Verastem
VSTM
$569M
| $3.82M | 1.61% | 1,865,000 -153,433 | -8% | -$315K |
|
23
Fulcrum Therapeutics
FULC
$351M
| $3.54M | 1.49% | 200,000 -122,500 | -38% | -$2.17M |
|
24
Iovance Biotherapeutics
IOVA
$807M
| $3.44M | 1.44% | 179,995 -194,500 | -52% | -$3.71M |
|
|
ALPN
25
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $3.19M | 1.34% | +230,000 | New | +$3.19M |
|